



Health Care Systems Research Collaboratory

Coordinating Center: Web team update

Asba Tasneem, PhD



Outline


- Website Analytics
- Grand Rounds
- SharePoint Updates
 - Bioethics supplement sites
 - SharePoint UH3 Interim Reports

WEB ANALYTICS



Web Analytics Summary (6 months)


- > 5,158 users
- > 38,948 page views




- > 49% new users
- ➤ 51% returning users



Unique visitors traffic




1. Session report by Country/Territory






Rethinking Clinical Trials


2. Session report by Metro area







Website Analytics: Top Ten Referral Traffic





Rethinking Clinical Trials

GRAND ROUNDS






Grand Rounds Operations


- Overview: Shared forum of Collaboratory and PCORnet
 - Format (30/30; chatpod, polling)
 - Dissemination: Live Tweets, Recordings, Slides
 - Metadata: Topic categorization, linking to related documents and articles
- History and Metrics
 - December 2012: ~50 subscribers
 - TODAY: 479 (958% increase!!)



Grand Rounds Snapshot



Website Analytics: Active Users



The number of unique users who had at least one session within the last day in your active date range.


The number of unique users who had at least one session within the last day in your active date range.

The number of unique users who had at least one session within the last day in your active date range.

The number of unique users who had at least one session within the last day in your active date range.



Website Analytics – Page views





Rethinking Clinical Trials

Top Ten Entrance pages & Time spent on each page

	Page Title	Entrances	Time on Page ▼
		6,576 % of Total: 100.00% (6,576)	394:23:50 % of Total: 100.00% (394:23:50)
1.	Home	3,212	38.95%
2.	Participant Engagment: Tools to Meet People Where They Are	283	0.91%
3.	Calendar - Grand Rounds: Rethinking Clinical Research	217	3.71%
4.	Pages - Grand Rounds	196	5.27%
5.	home	148	1.69%
6.	Events	137	1.16%
7.	Calendar - Grand Rounds: : Rethinking Clinical Research	128	0.94%
8.	SACHRP: Demonstration Project Regulatory and Ethics Support Documentation	110	1.98%
9.	NIH Collaboratory Distributed Research Network	84	1.04%
10.	EHR Data FAQs	82	0.27%





'All Things Grand Rounds' page

NIH Collaboratory About Us ▼ Demonstration Projects ▼ Cores ▼ News ▼ Collaboration Spaces

NIH Collaboratory >

Upcoming Grand Rounds

Grand Rounds: Robert M. Califf, MD, MACC - August 22 ™NEW

Grand Rounds: Consuelo H. Wilkins, MD, MSCI, and Yvonne Joosten, MPH -

August 29 ⊞ NEW

Grand Rounds: Sean Tunis, MD, MSc - 9/5/2014 Grand Rounds: David Kent, MD, MS - 9/12/2014 Grand Rounds: Jerry Suls, PhD - 9/19/2014

Grand Rounds: Tim Burdick, MD, MS - 9/26/2014

Grand Rounds: Chris Forrest, MD, PhD; Laura Schanberg, MD; and Peter

Margolis, MD, PhD - 10/3/2014


Grand Rounds: Jeffrey Jarvik, MD, MPH - October 10

Grand Rounds: Dalvir Gill, PhD- October 17 Grand Rounds: Susan Huang, MD - October 24

1 - 10 ▶

Most recent Grand Rounds





SHAREPOINT UPDATE





Bioethics Supplement Group Sites

- TiME Ethics Supplement group,
- ABATE Infection Trial Ethics Supplement group,
- Coordinating Center Ethics supplement group,
- Research on Medical Practice (RoMP) Group,
- NIH Bioethics group.



Bioethics Supplement Site: RoMP

Collaboratory Cores - Demonstration Projects - CC Operations - SC Leadership Bioethics Supplement Publications Committee Collab PMs Discussion Board UH3 Reporting


Bioethics Supplement → RoMPGroupPage

Welcome to the Research on Medical Practice (RoMP) group Collaboration space.

RoMP group has developed 3 videos. The first video describes why doctors do not always know which medication or treatment to give a patient. The methods researchers use to compare medications or treatments are described in the second video. The third video explores how patients might be told about this research.

Topics Covered in "Which Medication is Best?"


- · Influences on variation in usual medical care
- Doctors' uncertainty about usual medical care



Topics Covered in "Research on Medical Practices"

- · Medical record review
- Dandomization

Health Care Systems Research Collaboratory



https://rompethics.iths.org/



SharePoint UH3 Interim Reports: Features—

- Web based
- Pre-fill as much data as possible
- Secured Customized permissions
- Centralized resource for individual project teams
- Computerized checks of consistencies in reporting
- Able to accumulate data over time for meta analysis

Secured/Customized Sites







UH3 Interim Reports

Enrollment Forecast

THIS REPORT FORMAT SHOULD N	OT BE USED FOR DATA	COLLECTION FROM	STUDY PARTICIPANT	S
Principal Investigator:	Dember, Laura	Date:	8/18/2014	
Grant Title/Study Title (if different from Grant Title):	TiME	NIH Grant #:		
ClinicalTrials.gov NCD ID#(e.g. NCT0123456):				
Date of first UH3 notice of Grant				

•			THIS	REPORT FORMA	T SHOULD NO	T BE USED FOR	DATA COLL	LECTION FROM	STUDY PARTICI	PANTS					
			Principal	Investigator:		Dember, Lau	ra Da	ate:	8/18/2014						
ı				tle/Study Title t from Grant Title):		TiME	NI	IH Grant #:							
			ClinicalTr	rials.gov NCD IE)#(e.g.										
				first UH3 notice	of Grant										
•															
	61	Fiscal		0.6	01	Fiscal Y		04			l Year 3	61	01	Fisca	ıl Ye
	Q1 Expected	Q2 Expected	Q3 Expected		Q1 opected Total	Q2 Expected Total	Q3 Expected Total	Q4 I Expected Total	Q1 Expected Total	Q2 Expected Total	Q3 Expected Total	Q4 Expected Total	Q1 Expected Total	Q2 Expected Total	
		Total	Total	Total				iotai	iotai	iotai	iotai	iotai	iotai	iOtal	
Total # of clinical sites with active	Total	Total	Total 10	Total 5	0		50	50	50	50	50	50	50	50	50
subjects Total # of practitioners randomized (if	Total 10					50		50	50	50	50	50	50	50	
subjects	Total 10	10	10 45	10 5 50 5	0	50	50	50	50		50	50	50	50	50
subjects Total # of practitioners randomized (if applicable) Total # subjects screened/contacted to date (if applicable)	Total 10 25 30	10 35 40	10 45 50	10 5 50 5 100 2	0	50 50 300	50 50 500	50	50 700	50	50 900	50	50 2,000	50 2,500	50
subjects Total # of practitioners randomized (if applicable) Total # subjects screened/contacted to date (if applicable) Total # active subjects to date Total # subjects enrolled & lost,	Total 10 25	10 35	10 45	10 5 50 5 100 2	00	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50	50	50	50	50 900 650	50	50 2,000 1,500	50	3,0
subjects Total # of practitioners randomized (if applicable) Total # subjects screened/contacted to date (if applicable) Total # active subjects to date	Total 10 25 30 10	10 35 40 40	10 45 50 40	10 5 50 5 100 2 50 1	00000000	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 500 250	50 600 350	50 700 450	50 800 550	50 900	50 1,000 750	50 2,000	50 2,500 2,000	50



	Study Plan	
Target Numb	er of Clinical Sites:	50
Target Numb	er of Practitioners (if applicable):	
Total Enrollm	ent Target (including anticipated loss/withdrawals):	1000
Timeline for	Completing subject accrual:	5/15/2015
Length of ind	ividual subject involvement (screening through follow-up):	210 in days
Date of first	subject activity/enrollment in clinical trial:	9/24/2014
If no active s	ites/subjects, provide date trial is expected to begin:	

UH3 Interir	n R	epc	orts	5				
		Study P	lan					
Target Number of Clinica	ıl Sites:			50				
Target Number of Practit	ioners (if appli	cable):						
Total Enrollment Target (i	Total Enrollment Target (including anticipated loss/withdrawals):							
Timeline for Completing	subject accrua	ıl:		5/1	5/2015			
Length of individual subj	ect involvemer	nt (screening th	rough follow	up): 210) in da	ys		
Date of first subject activ	vity/enrollment	t in clinical tri	al:	9/2	4/2014			
				in		00000000		
If no active sites/subject IF ANY OF THIS INFO			_		r Prograi	M OFFICER		
	RMATION HAS	CHANGED, P	NUMBE	TACT YOU	CUMMU	M OFFICER		
IF ANY OF THIS INFO	RMATION HAS ACTIVITY TA	CHANGED, P ABLE (ALL porting Date	NUMBEI	TACT YOU	Q3 Repo	M OFFICER LATIVE) orting Date	Q4 R	
IF ANY OF THIS INFO	RMATION HAS ACTIVITY TA Q1 Rep	CHANGED, P ABLE (ALL porting Date muary 1st	NUMBEI	RS ARE (ting Date	Q3 Repo	M OFFICER LATIVE) orting Date by 1st		
IF ANY OF THIS INFO	ACTIVITY TA Q1 Rep Jan Data: 4/1 Expecte	ABLE (ALL porting Date huary 1st	NUMBE Q2 Repor Apri	RS ARE (ting Date I 1st	Q3 Repo Jul Expected	M OFFICER LATIVE) orting Date y 1st Actual	O Expect	cto
IF ANY OF THIS INFO	ACTIVITY TA Q1 Rep Jan Data: 4/1	CHANGED, P ABLE (ALL porting Date nuary 1st /2014	NUMBE Q2 Repor	RS ARE (ting Date	Q3 Repo	M OFFICER LATIVE) orting Date ly 1st	0	cto
ENROLLMENT A	ACTIVITY TA Q1 Rep Jan Data: 4/1 Expecte Total 10	ABLE (ALL porting Date nuary 1st /2014	NUMBE Q2 Repor Apri Expected Total	RS ARE (ting Date I 1st Actual Total	Q3 Repo Jul Expected Total	M OFFICER LATIVE) orting Date y 1st Actual Total	Expect Tota	cto
ENROLLMENT A Effective Date of Total # of clinical sites with active subjects Total # of practitioners randomized (if applical Total # subjects screened/contacted to date (if applicable)	Q1 Rep Jan Data: 4/1 Expecte Total 10 ble) 25	ABLE (ALL porting Date luary 1st 2014 and Actual Total 4	NUMBE Q2 Repor Apri Expected Total	RS ARE (ting Date I 1st Actual Total	Q3 Repo Jul Expected Total	LATIVE) Orting Date y 1st Actual Total	Expect Tota	cto
ENROLLMENT A Effective Date of Total # of clinical sites with active subjects Total # of practitioners randomized (if applical Total # subjects screened/contacted to date (if applicable) Total # active subjects to date	CTIVITY TA Q1 Rep Jan Data: 4/1 Expecte Total 10 ble) 25 f 30	ABLE (ALL corting Date duary 1st /2014 ed Actual Total 4 20	NUMBE Q2 Repor Apri Expected Total 10	RS ARE (ting Date I 1st Actual Total 7	Q3 Repo Jul Expected Total 10	M OFFICER LATIVE) Orting Date y 1st Actual Total 10 45	Expect Tota 10	cto
ENROLLMENT A Effective Date of Total # of clinical sites with active subjects Total # of practitioners randomized (if applical Total # subjects screened/contacted to date (if applicable)	CTIVITY TA Q1 Rep Jan Data: 4/1 Expecte Total 10 ble) 25 f 30	ABLE (ALL porting Date puary 1st //2014	NUMBE Q2 Repor Apri Expected Total 10 35 40	RS ARE (ting Date I 1st Actual Total 7 30 15	Q3 Reported Total 10 45	Actual Total 10 45	Expect Tota 10 50	cto

g Clinical Trials



Quarterly Enrollment Inclusion Activity


THIS REPORT FORMAT SHOULD NOT BE USED FOR DATA COLLECTION FROM STUDY PARTICIPANTS

Principal Investigator:	Dember, Laura	Date:	2014-06-16
Grant Title/Study Title (if different from Grant Title):	TIME	Fiscal Year	FY1
ClinicalTrials.gov NCD ID#(e.g. NCT0123456):		Quarter:	Q1
Date of first UH3 notice of Grant Award:		NIH Grant #:	

				Eth	nnic Catego	ries					
Racial Categories	Not	Not Hispanic or Latino			spanic or Lat	ino	Unknown/Not Reported Ethnicity			Totals	
	Female	Male	Unknown	Female	Male	Unknown	Female	Male	Unknown		
American Indian/Alaska Native	500	250	200	200	100	50	25	50	25	1,400	
Asian	150	20	25	0	0	0	0	0	0	195	
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0	
Black or African American	0	0	0	0	0	0	0	0	0	0	
White	1,000	250	300	0	0	0	0	0	0	1,550	
More Than One Race	0	0	0	0	0	0	0	0	0	0	
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0	
Total	1,500	520	525	200	100	50	25	50	25		

Dashboard: Snapshot


Cumulative Enrollment Curve






8

Dashboard: Race/Ethnicity/Gender












Roll Up Dashboard

All Studies: Enrollment Curve





Thank you!

Questions?



Web Analytics: Session by Geo Location

- 1. Sessions report by Country/Territory
- 2. Sessions report by Metro
- 3. Sessions report by City

Session: A session is the period time a user is actively engaged with your website, app, etc. All usage data (Screen Views, Events, Ecommerce, etc.) is associated with a session.

